

World Journal of *Gastroenterology*

World J Gastroenterol 2022 August 14; 28(30): 4019-4234



REVIEW

- 4019 Role of one-step nucleic acid amplification in colorectal cancer lymph node metastases detection
Crafa F, Vanella S, Catalano OA, Pomykala KL, Baiamonte M

MINIREVIEWS

- 4044 Current perspectives on the role of liver transplantation for Langerhans cell histiocytosis: A narrative review
Menon J, Rammohan A, Vij M, Shanmugam N, Rela M
- 4053 Gut microbiota, inflammatory bowel disease and colorectal cancer
Quaglio AEV, Grillo TG, De Oliveira ECS, Di Stasi LC, Sasaki LY
- 4061 Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures
Gallo P, Terracciani F, Di Pasquale G, Esposito M, Picardi A, Vespasiani-Gentilucci U

ORIGINAL ARTICLE

Basic Study

- 4075 P2X7 receptor blockade decreases inflammation, apoptosis, and enteric neuron loss during *Clostridioides difficile* toxin A-induced ileitis in mice
Santos AAQA, Costa DVS, Foschetti DA, Duarte ASG, Martins CS, Soares PMG, Castelucci P, Brito GAC

Case Control Study

- 4089 Serological profiling of Crohn's disease and ulcerative colitis patients reveals anti-microbial antibody signatures
Shome M, Song L, Williams S, Chung Y, Murugan V, Park JG, Faubion W, Pasha SF, Leighton J, LaBaer J, Qiu J

Retrospective Cohort Study

- 4102 Trends in medication use and treatment patterns in Chinese patients with inflammatory bowel disease
Yao LY, Shao BL, Tian F, Ye M, Li YQ, Wang XL, Wang L, Yang SQ, Lv XP, Jia Y, Wang XH, Zhang XQ, Wei YL, Cao Q

Retrospective Study

- 4120 Salivary *Fusobacterium nucleatum* serves as a potential diagnostic biomarker for gastric cancer
Chen WD, Zhang X, Zhang MJ, Zhang YP, Shang ZQ, Xin YW, Zhang Y
- 4133 Development and validation of a nomogram for predicting overall survival in cirrhotic patients with acute kidney injury
Wan YP, Wang AJ, Zhang W, Zhang H, Peng GH, Zhu X

- 4152** Cumulative incidence and risk factors for pouch adenomas associated with familial adenomatous polyposis following restorative proctocolectomy

Ryu HS, Yu CS, Kim YI, Lee JL, Kim CW, Yoon YS, Park IJ, Lim SB, Kim JC

- 4163** Changes in the esophagogastric junction outflow obstruction manometric feature based on the Chicago Classification updates

Li YY, Lu WT, Liu JX, Wu LH, Chen M, Jiao HM

Observational Study

- 4174** Epidemiology of inflammatory bowel diseases in the state of Rio Grande do Sul, Brazil

Cassol OS, Zobot GP, Saad-Hossne R, Padoin A

- 4182** Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study

Choi GH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Lee HC, Jang JW, Ki M, Choi HY, Baik D, Jeong SH

META-ANALYSIS

- 4201** Network meta-analysis of randomized controlled trials on esophagectomies in esophageal cancer: The superiority of minimally invasive surgery

Szakó L, Németh D, Farkas N, Kiss S, Dömötör RZ, Engh MA, Hegyi P, Eross B, Papp A

CASE REPORT

- 4211** Contrast-enhanced ultrasound of a traumatic neuroma of the extrahepatic bile duct: A case report and review of literature

Yuan ZQ, Yan HL, Li JW, Luo Y

LETTER TO THE EDITOR

- 4221** Prognostic role of expression of angiogenesis markers in hepatocellular carcinoma: A bioinformatics analysis

Miao YD, Tang XL, Wang JT, Mi DH

- 4227** Benefits of minimally invasive surgery in the treatment of gastric cancer

Sibio S, La Rovere F, Di Carlo S

- 4231** Alcohol-related diseases and liver metastasis: Role of cell-free network communication

Muro M, Collados-Ros A, Legaz I

ABOUT COVER

Associate Editor of *World Journal of Gastroenterology*, Ming-Lung Yu, MD, PhD, Chair Professor, Chief, Hepatitis Research Center, Kaohsiung Medical University, No. 100 Tzyou 1st Road, Kaohsiung 807, Taiwan.
fish6069@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yu; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

August 14, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Benefits of minimally invasive surgery in the treatment of gastric cancer

Simone Sibio, Francesca La Rovere, Sara Di Carlo

Specialty type: Gastroenterology and hepatology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D, D, D

Grade E (Poor): E

P-Reviewer: Jheng YC, Taiwan; Khaled I, Egypt; Sun Q, China; Viswanath YK, United Kingdom; Yao K, China

Received: November 17, 2021

Peer-review started: November 17, 2021

First decision: December 26, 2021

Revised: January 8, 2022

Accepted: July 22, 2022

Article in press: July 22, 2022

Published online: August 14, 2022



Simone Sibio, Francesca La Rovere, Department of Surgery P. Valdoni, Unit of Oncologic and Minimally Invasive Surgery, Sapienza University of Rome, Umberto I University Hospital, Rome 00161, Italy

Sara Di Carlo, Minimally Invasive Surgery Unit, Department of Surgery, Tor Vergata University, Rome 00133, Italy

Corresponding author: Simone Sibio, PhD, Associate Professor, Consultant Physician-Scientist, Lecturer, Surgical Oncologist, Department of Surgery P. Valdoni, Unit of Oncologic and Minimally Invasive Surgery, Sapienza University of Rome, Umberto I University Hospital, Viale del Policlinico 155, Rome 00161, Italy. simone.sibio@uniroma1.it

Abstract

We read with great interest the article that retrospectively analyzed 814 patients with primary gastric cancer, who underwent minimally invasive R0 gastrectomy between 2009 and 2014 by grouping them in laparoscopic *vs* robotic procedures. The results of the study highlighted that age, American Society of Anesthesiologists status, gastrectomy type and pathological T and N status were the main prognostic factors of minimally invasive gastrectomy and showed how the robotic approach may improve long-term outcomes of advanced gastric cancer. According to most of the current literature, robotic surgery is associated with a statistically longer operating time when compared to open and laparoscopic surgery; however, looking at the adequacy of resection, defined by negative surgical margins and number of lymph nodes removed, it seems that robotic surgery gives better results in terms of the 5-year overall survival and recurrence-free survival. The robotic approach to gastric cancer surgery aims to overcome the difficulties and technical limitations of laparoscopy in major surgery. The three-dimensional vision, articulation of the instruments and good ergonomics for the surgeon allow for accurate and precise movements which facilitate the complex steps of surgery such as lymph node dissection, esophagus-jejunal anastomosis packaging and reproducing the technical accuracy of open surgery. If the literature, as well as the analyzed study, offers us countless data regarding the short-term oncological results of robotic surgery in the treatment of gastric cancer, satisfactory data on long-term follow-up are lacking, so future studies are necessary.

Key Words: Gastric cancer; Robotic gastrectomy; Laparoscopy; D2 lymphadenectomy; Long-term outcomes; Morbidity

Core Tip: Laparoscopic and robotic approaches are compared in the treatment of gastric cancer focusing on the prognostic factors as well as the oncological benefits brought about. While the long-term outcomes of laparoscopic surgery have been increasingly cited in recent years, only a few studies have analyzed the long-term results of the robotic approach, underlining the importance of future studies. A relevant aspect of robotic gastrectomy is the possibility to perform a more accurate lymph node dissection, which results in a longer survival with advanced gastric cancers.

Citation: Sibio S, La Rovere F, Di Carlo S. Benefits of minimally invasive surgery in the treatment of gastric cancer. *World J Gastroenterol* 2022; 28(30): 4227-4230

URL: <https://www.wjgnet.com/1007-9327/full/v28/i30/4227.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v28.i30.4227>

TO THE EDITOR

We read with interest the Nakauchi *et al*[1] study, which retrospectively examined 814 patients with primary gastric cancer undergoing a minimally invasive R0 gastrectomy, between 2009 and 2014 in Kanazawa (Japan), comparing the laparoscopic and robotic approach and looking at the 5-year overall survival (OS) and recurrence-free survival (RFS). We were pleased to see from the results of the study that the robotic approach could improve the long-term outcomes of advanced gastric cancer. The authors observed that the robotic approach led to significantly better RFS compared to the laparoscopic one in patients with p-Stage II/III tumors, although no significant difference in OS was detected, nor in OS and RFS in p-Stage patients treated with laparoscopy or robotics.

The study also revealed that age > 65 years, American Society of Anesthesiologists physical status 3, total or proximal gastrectomy, and disease status T4 and N positive, are all independent prognostic factors[1]. Since gastric cancer is the fifth most common malignancy in the world and the third cause of cancer death, it is worth it to identify the most appropriate technical approach for this disease being minimally invasive surgery the standard approach for several GI surgery procedures[2,3].

Surgical treatment remains the only therapeutic option with curative intent. Total or subtotal gastrectomy, associated with D2 lymphadenectomy, represents the therapeutic gold standard for gastric cancer. We must acknowledge that the traditional surgical approach, open surgery, remains the most widespread surgical technique. Although, laparoscopy has become almost constant in general surgery, the use of the laparoscopic technique for gastric surgery is yet scarce in the case of malignancies. As supported by various authors, laparoscopy has several technical drawbacks and limitations, including two-dimensional vision, stiffness of instruments, limited range of motion, amplification of hand tremors and uncomfortable surgical placement which makes some fundamental surgical steps, such as D2 lymphadenectomy, extremely complex[2,4].

According to the paper discussed, the pN factor is strongly associated with survival after gastric cancer treatment, confirming the thesis that laparoscopy in gastric cancer is more adequate in the earlier stages. In contrast, the safety and oncological adequacy of laparoscopic-assisted radical D2 gastrectomy for advanced gastric cancer are still under discussion[5]. From the meta-analysis, it emerges that the main variables associated with a statistically significant advantage of laparoscopic technique over open surgery are represented by: Reduced blood loss, lower complication rate, faster recovery and reduced pain at the expense of a longer surgical time and fewer lymph nodes removed, therefore a potential worse local control of the disease[6,7].

Alongside laparoscopy, robotic technology allows us to overcome the technical difficulties of laparoscopy, thanks to the three-dimensional vision, instruments' articulation and greater ergonomics for the surgeon, offering a better therapeutic approach to the minimally invasive treatment of stomach tumors. Thus, the short and medium term results of robotic gastric surgery can be almost compared with open and laparoscopic procedure when taken into account surgeon experience and technical implementation of the robotic system.

We fully agree with the authors, who have shown a significantly lower morbidity in the group of patients treated with robotics than in the laparoscopic group, as widely discussed in many studies. A recent meta-analysis, which compared laparoscopy with robotics in the treatment of gastric cancer, highlighted that the robotic approach appears to achieve better surgical results in the short term, also thanks to the ability to recover a greater number of lymph nodes, namely lymph nodes in station n. 7, 8a, 9 and 11p, which are avowedly more difficult to reach, ensuring a more appropriate staging and chemotherapy plan[8].

A study conducted in Japan reported, among the advantages of robotic surgery, a lower intraoperative blood loss, with a consequent reduction in the dissemination of cancer cells in the peritoneal cavity during surgery and, therefore, a better prognosis. Another aspect highlighted is a lower risk of dehiscence of the esophagus-jejunal anastomosis, along with a lower incidence of internal hernias[9-11]. From the short-term results it emerges that robotic gastrectomy is a safe technique that potentially allows to extend the number of patients treatable with a minimally invasive approach, overcoming the technical difficulties of laparoscopy, offering some benefits in terms of blood loss, conversion rate, overall number of lymph nodes removed and in suprapancreatic areas, procedure-specific postoperative morbidity and shorter length of hospital stay[12].

Robotic gastrectomy is a safe and effective surgical technique when performed by experienced surgeons, however, it is associated with a longer operative time and a higher economic value than laparoscopic and open approaches[13,14]. Indeed, one of the factors that slows down the spread of robotic surgery is the particular technical expertise required while handling the robotic devices, resulting in a steeper learning curve for the specialized operator. The cost and longer timeframe of robotics make future studies necessary[15], as well as the need for randomized controlled trials comparing the two techniques with a long-term follow-up, on which publications are still scarce given the relatively recent diffusion of the technique[16].

Given the greater cost of robotics, we want to underline one of the limitations of the study discussed here, represented by possible errors in the selection of patients. The availability of robotic devices is strongly dependent on the wealth of the country and of the individual; both patients who are aware of the advantages of the robotic approach and experienced surgeons who are able to perform this novel technique could lead to an overuse of the technique. In Western countries, robotic devices are associated with longer operative time, and higher costs but fewer post-operative complications resulting in lower hospitalization costs, and shorter hospital stays[17].

In conclusion, the study discussed here provides valid results on the correct therapeutic management of patients with gastric cancer, with the aim to bridge over some of the difficulties and technical limitations that laparoscopy encounters in major surgery. Essentially, laparoscopic D2 lymphadenectomy remains a challenging procedure: In particular, the dissection of the lymph nodes along the celiac, hepatic and splenic arteries makes this approach technically complicated and time-consuming even for well-trained surgeons. It is in this context that robotic surgery is worth looking at and it represents a useful tool that overcomes some limitations of conventional laparoscopic techniques, even if greater surgical and anesthetic times and the higher costs have to be considered when compared to open surgery.

Although, in accordance with the international literature that ascribes better results to robotic surgery in perioperative outcomes in terms of blood loss, and postoperative complications, future studies of higher quality are necessary due to the lack of data on long-term results, given the relatively recent diffusion of the technique. In a long-term perspective, considering the need for further studies on larger samples of patients from Western countries, we believe that robotic technology for gastric cancer surgery, taking into account the many advantages it offers, can become a gold standard[18].

FOOTNOTES

Author contributions: La Rovere F and Di Carlo S equally contributed in writing the draft; Di Carlo S revised the English language; Sibio S revised and approved the draft.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Italy

ORCID number: Simone Sibio 0000-0002-5694-951X; Francesca La Rovere 0000-0001-8561-1406; Sara Di Carlo 0000-0001-6519-991X.

S-Editor: Wang JJ

L-Editor: Filipodia

P-Editor: Wang JJ

REFERENCES

- 1 **Nakauchi M**, Suda K, Shibasaki S, Nakamura K, Kadoya S, Kikuchi K, Inaba K, Uyama I. Prognostic factors of minimally invasive surgery for gastric cancer: Does robotic gastrectomy bring oncological benefit? *World J Gastroenterol* 2021; **27**: 6659-6672 [PMID: [34754159](#) DOI: [10.3748/wjg.v27.i39.6659](#)]
- 2 **Amelio I**, Bertolo R, Bove P, Buonomo OC, Candi E, Chiocchi M, Cipriani C, Di Daniele N, Ganini C, Juhl H, Mauriello A, Marani C, Marshall J, Montanaro M, Palmieri G, Piacentini M, Sica G, Tesaro M, Rovella V, Tisone G, Shi Y, Wang Y, Melino G. Liquid biopsies and cancer omics. *Cell Death Discov* 2020; **6**: 131 [PMID: [33298891](#) DOI: [10.1038/s41420-020-00373-0](#)]
- 3 **Amelio I**, Bertolo R, Bove P, Candi E, Chiocchi M, Cipriani C, Di Daniele N, Ganini C, Juhl H, Mauriello A, Marani C, Marshall J, Montanaro M, Palmieri G, Piacentini M, Sica G, Tesaro M, Rovella V, Tisone G, Shi Y, Wang Y, Melino G. Cancer predictive studies. *Biol Direct* 2020; **15**: 18 [PMID: [33054808](#) DOI: [10.1186/s13062-020-00274-3](#)]
- 4 **EuroSurg Collaborative**. Body mass index and complications following major gastrointestinal surgery: a prospective, international cohort study and meta-analysis. *Colorectal Dis* 2018; **20**: O215-O225 [PMID: [29897171](#) DOI: [10.1111/codi.14292](#)]
- 5 **Ojima T**, Nakamura M, Nakamori M, Hayata K, Katsuda M, Kitadani J, Maruoka S, Shimokawa T, Yamaue H. Robotic versus laparoscopic gastrectomy with lymph node dissection for gastric cancer: study protocol for a randomized controlled trial. *Trials* 2018; **19**: 409 [PMID: [30064474](#) DOI: [10.1186/s13063-018-2810-5](#)]
- 6 **Cai J**, Wei D, Gao CF, Zhang CS, Zhang H, Zhao T. A prospective randomized study comparing open versus laparoscopy-assisted D2 radical gastrectomy in advanced gastric cancer. *Dig Surg* 2011; **28**: 331-337 [PMID: [21934308](#) DOI: [10.1159/000330782](#)]
- 7 **Lee HJ**, Hyung WJ, Yang HK, Han SU, Park YK, An JY, Kim W, Kim HI, Kim HH, Ryu SW, Hur H, Kong SH, Cho GS, Kim JJ, Park DJ, Ryu KW, Kim YW, Kim JW, Lee JH, Kim MC; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT). *Ann Surg* 2019; **270**: 983-991 [PMID: [30829698](#) DOI: [10.1097/SLA.0000000000003217](#)]
- 8 **Garbarino GM**, Costa G, Laracca GG, Castagnola G, Mercantini P, Di Paola M, Vita S, Masoni L. Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer in middle-low-volume centers in Western countries: a propensity score matching analysis. *Langenbecks Arch Surg* 2020; **405**: 797-807 [PMID: [32754848](#) DOI: [10.1007/s00423-020-01951-7](#)]
- 9 **Guerrini GP**, Esposito G, Magistri P, Serra V, Guidetti C, Olivieri T, Catellani B, Assirati G, Ballarin R, Di Sandro S, Di Benedetto F. Robotic versus laparoscopic gastrectomy for gastric cancer: The largest meta-analysis. *Int J Surg* 2020; **82**: 210-228 [PMID: [32800976](#) DOI: [10.1016/j.ijssu.2020.07.053](#)]
- 10 **Pan HF**, Wang G, Liu J, Liu XX, Zhao K, Tang XF, Jiang ZW. Robotic Versus Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer. *Surg Laparosc Endosc Percutan Tech* 2017; **27**: 428-433 [PMID: [29211699](#) DOI: [10.1097/SLE.0000000000000469](#)]
- 11 **Sica GS**, Djapardj V, Westaby S, Maynard ND. Diagnosis and management of aorto-esophageal fistula caused by a foreign body. *Ann Thorac Surg* 2004; **77**: 2217-2218 [PMID: [15172312](#) DOI: [10.1016/j.athoracsur.2003.06.031](#)]
- 12 **Li ZY**, Zhou YB, Li TY, Li JP, Zhou ZW, She JJ, Hu JK, Qian F, Shi Y, Tian YL, Gao GM, Gao RZ, Liang CC, Shi FY, Yang K, Wen Y, Zhao YL, Yu PW; Robotic, Laparoscopic Surgery Committee of Chinese Research Hospital Association. Robotic Gastrectomy versus Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Cohort Study of 5402 Patients in China. *Ann Surg* 2021 [PMID: [34225299](#) DOI: [10.1097/SLA.0000000000005046](#)]
- 13 **Ma J**, Li X, Zhao S, Zhang R, Yang D. Robotic versus laparoscopic gastrectomy for gastric cancer: a systematic review and meta-analysis. *World J Surg Oncol* 2020; **18**: 306 [PMID: [33234134](#) DOI: [10.1186/s12957-020-02080-7](#)]
- 14 **Giuliani G**, Guerra F, De Franco L, Salvischiani L, Benigni R, Coratti A. Review on Perioperative and Oncological Outcomes of Robotic Gastrectomy for Cancer. *J Pers Med* 2021; **11** [PMID: [34357105](#) DOI: [10.3390/jpm11070638](#)]
- 15 **Zhang Z**, Zhang X, Liu Y, Li Y, Zhao Q, Fan L, Zhang Z, Wang D, Zhao X, Tan B. Meta-analysis of the efficacy of Da Vinci robotic or laparoscopic distal subtotal gastrectomy in patients with gastric cancer. *Medicine (Baltimore)* 2021; **100**: e27012 [PMID: [34449473](#) DOI: [10.1097/MD.00000000000027012](#)]
- 16 **Hu LD**, Li XF, Wang XY, Guo TK. Robotic versus Laparoscopic Gastrectomy for Gastric Carcinoma: a Meta-Analysis of Efficacy and Safety. *Asian Pac J Cancer Prev* 2016; **17**: 4327-4333 [PMID: [27797239](#)]
- 17 **Caruso R**, Vicente E, Núñez-Alfonso J, Ferri V, Diaz E, Fabra I, Malave L, Duran H, Isernia R, D'Ovidio A, Pinna E, Ielpo B, Quijano Y. Robotic-assisted gastrectomy compared with open resection: a comparative study of clinical outcomes and cost-effectiveness analysis. *J Robot Surg* 2020; **14**: 627-632 [PMID: [31620970](#) DOI: [10.1007/s11701-019-01033-x](#)]
- 18 **Shibasaki S**, Suda K, Obama K, Yoshida M, Uyama I. Should robotic gastrectomy become a standard surgical treatment option for gastric cancer? *Surg Today* 2020; **50**: 955-965 [PMID: [31512060](#) DOI: [10.1007/s00595-019-01875-w](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

